AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 17 - (NewsRx.com & NewsRx.net) -- Wyeth Pharmaceuticals, a division of Wyeth (WYE), announced that it has updated the package inserts for its postmenopausal hormone therapies Prempro (conjugated estrogens/medroxyprogesterone acetate tablets), Premphase (conjugated estrogens/medroxyprogesterone acetate tablets), and Premarin (conjugated estrogens tablets, USP).
This update reflects recent safety information, primarily from the NIH study known as the Women's Health Initiative (WHI). The company initiated this action so physicians will have up-to-date information in order to counsel their postmenopausal patients on appropriate use of its hormone therapies. Wyeth has sent letters to physicians informing them about the update.
Besides including the WHI findings, the updated labels also state that:
* These products are not indicated and should not be used to prevent coronary ...
Source: HighBeam Research, Wyeth updates product labels for its postmenopausal hormone...